OpenAlex konusu

Cancer Treatment and Pharmacology

Bu sayfa OpenAlex konu etiketine göre çalışmaları ve o konuda görünen akademisyenleri listeler. YÖKSİS temel alan / yan dal değildir.

OpenAlex 2.316 eser 61 yazar konusu

Çalışmalar

2.316 eser

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer 2019
YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.9%
BACKGROUND: Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)-targeted therapy have a worse prognosis than those who have no residual cancer. Trastuzumab emtansine (T-DM1), an antibody-drug conjugate of trastuzumab and the cy…
- EMİN TAMER ELKIRAN
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma 2018
YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%
BACKGROUND: The combination of bortezomib, melphalan, and prednisone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. Daratumumab has shown efficacy in combination with standard-of-care regimens in patients with relapsed or refracto…
- FİLİZ VURAL
Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy 2006
YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 98.4%
Özet henüz yok.
- ALİ DOĞAN
Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy 2006
YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 98.4%
Özet henüz yok.
- ABDURRAHMAN OĞUZHAN
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. 2016
YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.8%
Özet henüz yok.
- ERHAN GÖKMEN
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial 2019
YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.8%
Özet henüz yok.
- FEVZİ ALTUNTAŞ
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial 2019
YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.8%
Özet henüz yok.
- MEHMET SÖNMEZ
Natural Products/Bioactive Compounds as a Source of Anticancer Drugs 2022
YÖKSİS SJR Q1 JCR Q2 OpenAlex üst %1 OpenAlex 99.7%
Cancer is one of the major deadly diseases globally. The alarming rise in the mortality rate due to this disease attracks attention towards discovering potent anticancer agents to overcome its mortality rate. The discovery of novel and effective anticancer agents from natural sources has been the main point of interes…
- ULAŞ ACARÖZ
Natural Products/Bioactive Compounds as a Source of Anticancer Drugs 2022
YÖKSİS SJR Q1 JCR Q2 OpenAlex üst %1 OpenAlex 99.7%
Cancer is one of the major deadly diseases globally. The alarming rise in the mortality rate due to this disease attracks attention towards discovering potent anticancer agents to overcome its mortality rate. The discovery of novel and effective anticancer agents from natural sources has been the main point of interes…
- DAMLA ARSLAN ACARÖZ
Natural Products/Bioactive Compounds as a Source of Anticancer Drugs 2022
YÖKSİS SJR Q1 JCR Q2 OpenAlex üst %1 OpenAlex 99.7%
Cancer is one of the major deadly diseases globally. The alarming rise in the mortality rate due to this disease attracks attention towards discovering potent anticancer agents to overcome its mortality rate. The discovery of novel and effective anticancer agents from natural sources has been the main point of interes…
- SİNAN İNCE
Natural Products/Bioactive Compounds as a Source of Anticancer Drugs 2022
YÖKSİS SJR Q1 JCR Q2 OpenAlex üst %1 OpenAlex 99.7%
Cancer is one of the major deadly diseases globally. The alarming rise in the mortality rate due to this disease attracks attention towards discovering potent anticancer agents to overcome its mortality rate. The discovery of novel and effective anticancer agents from natural sources has been the main point of interes…
- HAYRİ DEMİRBAŞ
Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation 2018
YÖKSİS OpenAlex üst %1 OpenAlex 99.3%
Özet henüz yok.
- NEŞET KÖKSAL

Akademisyenler

61 akademisyen